Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Joshua J. Solomon(National Jewish Health), Marilyn K. Glassberg(University of Miami), Isabel Amigues, Jeffrey A. Golden(University of California, San Francisco), Kevin R. Flaherty(University of Michigan), Rie Maurer(Brigham and Women's Hospital), Mary Beth Scholand(University of Utah), Ganesh Raghu(University of Washington), Gerard Cox, David A. Lynch(McMaster University), Nazia Chaudhuri(University of Ulster), Hilary J. Goldberg(Harvard University), Ian Glaspole(Monash University), Bibek Gooptu(King's College London), Iván O. Rosas(Brigham and Women's Hospital), Robert Vassallo(Mayo Clinic), Michael Gibbons(University of Exeter), Lauren Troy(The University of Sydney), Kristina Eliopoulos, Daniel C. Chambers(Prince Charles Hospital), Tracy J. Doyle(Brigham and Women's Hospital), Cathie Spino(University of Michigan), John Huntwork, Lisa Spencer(University of Liverpool), Chris Glynn, Huzaifa Adamali, Andrew H. Limper(Mayo Clinic), Shana Haynes-Harp, Mark A. Perrella(Brigham and Women's Hospital), John M. Davis(Mayo Clinic), Coimbatore Sree Vidya, Sarah E. Collins, Paul F. Dellaripa(Brigham and Women's Hospital), Felix Woodhead(University of Leicester), F. Poli, Sonye K. Danoff(Johns Hopkins University), Stephen M. Humphries(National Jewish Health), Timothy Clouser, Maria I. Danila(University of Alabama at Birmingham), Ian Forrest(Royal Victoria Infirmary), Joseph A. Lasky(Tulane University), Jemima F. Albayda, Anthony H. Maeda, Martin Kolb(McMaster University), Shelley Hurwitz(Harvard University), Steve Duncan(University of Pittsburgh), Karthik Suresh(Johns Hopkins University), Rebecca R. Baron, Kristin B. Highland
The Lancet Respiratory Medicine
September 5, 2022
Cited by 211


Related Papers